Evidence map›Paper›PMID 24399866›Full record

ArticleActa myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology2013

A novel homozygous mutation at the GAA gene in Mexicans with early-onset Pompe disease.

Carmen Esmer, Rosario Becerra-Becerra, Claudia Peña-Zepeda, Antonio Bravo-Oro

Open access · greenAbstract readCase Reports
In one paragraph

Article in Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Carmen EsmerDepartment of Genetics, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, México; ; School of Medicine, Universidad Cuauhtémoc, San Luis Potosí, México;
Rosario Becerra-BecerraDepartment of Pediatric Cardiology, Hospital Central "Dr. Ignacio Morones Prieto, San Luís Potosí, México;
Claudia Peña-ZepedaDepartment of Pathology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, México;
Antonio Bravo-OroDepartment of Neuropediatrics, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, México.
Hospital Central Dr. Ignacio Morones Prieto · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycogen-storage disease type II, also named Pompe disease, is caused by the deficiency of the enzyme acid alpha-glucosidase, which originates lysosomal glycogen accumulation leading to progressive neuromuscular damage. Early-onset Pompe disease shows a debilitating and frequently fulminating course. To date, more than 300 mutations have been described; the majority of them are unique to each affected individual. Most early-onset phenotypes are associated with frameshift mutations leading to a truncated alpha-glucosidase protein with loss of function. Founder effects are responsible from many cases from few highprevalence world regions. Herein we described two apparently unrelated cases affected with classical early-onset Pompe disease, both pertaining to a small region from Central Mexico (the State of San Luis Potosí), the same novel homozygous frameshift mutation at gene GAA (c.1987delC) was demonstrated in both cases. This GAA gene deletion implies a change of glutamine to serine at codon 663, and a new reading frame that ends after 33 base pairs, which leads to the translation of a truncated protein. This report contributes to widen the knowledge on the effect of pathogenic mutations in Pompe disease. Here we postulate the existence of a founder effect.

Indexed as

alpha-GlucosidasesGlycogen Storage Disease Type IICardiomegalyFatal OutcomeFounder EffectGenetic Predisposition to DiseaseHomozygoteHumansInfantMaleMexicoMutationRadiographyalpha-GlucosidasesGAA protein, humanAcid maltase deficiencyEarly-onset Pompe diseaseFounder effect

Identifiers

PMID24399866
PMCPMC3866899
OpenAlexW93658133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.